Istituto Di Ricerche Farmacologiche Mario Negri
Istituto Di Ricerche Farmacologiche Mario Negri is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study
Sponsor Universita' Vita-salute S. Raffaele
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuxiMAb or BevacizumaB
Sponsor Azienda USL IRCCS Di Reggio Emilia
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, phase IIb study of adjuvant durvalumab (MEDI4736) plus regorafenib vs untreated control in stage IV colorectal cancer patients with no evidence of disease (NED): VIVA trial
Sponsor IRCCS Ospedale Policlinico San Martino
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Istituto Di Ricerche Farmacologiche Mario Negri?
The 2026-10-09 snapshot links Istituto Di Ricerche Farmacologiche Mario Negri to 3 distinct CTIS trials. Recorded services include Data management, Safety reporting & pharmacovigilance, Statistical analysis, Clinical monitoring, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Istituto Di Ricerche Farmacologiche Mario Negri?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Istituto Di Ricerche Farmacologiche Mario Negri conducted?
The linked trials record locations in 1 country, including Italy. These are trial locations, not confirmed office locations or countries where Istituto Di Ricerche Farmacologiche Mario Negri delivered services.
What can this page tell me about Istituto Di Ricerche Farmacologiche Mario Negri's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Istituto Di Ricerche Farmacologiche Mario Negri. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Istituto Di Ricerche Farmacologiche Mario Negri